Table 4. Comparison of health status and quality of life 1 week after diagnosis for patients with and without cancer.
| Parameter; mean (s.d.) | Alla | Cancerb | No cancerc | Difference (95% CI) | P-value |
|---|---|---|---|---|---|
| SF36 PCS | |||||
| Colorectal | 46.29 (10.66) | 41.54 (7.52) | 46.58 (10.78) | 5.04 (−3.84–13.92) | 0.26 |
| Lung | 37.81 (11.75) | 36.94 (11.64) | 41.37 (11.88) | 4.43 (−2.06–10.93) | 0.18 |
| Prostate | 50.27 (10.01) | 52.04 (11.04) | 49.23 (9.28) | −2.81 (−6.80–1.18) | 0.16 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| SF36 MCS | |||||
| Colorectal | 48.75 (10.40) | 49.28 (8.79) | 48.71 (10.53) | −0.57 (−9.29–8.15) | 0.90 |
| Lung | 42.71 (15.14) | 42.54 (14.34) | 43.40 (18.59) | 0.86 (−7.61–9.32) | 0.84 |
| Prostate | 52.57 (9.08) | 50.49 (10.11) | 53.80 (8.25) | 3.31 (−0.29–6.90) | 0.07 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| HADS Anxiety | |||||
| Colorectal | 3.37 (1.09) | 3.17 (0.98) | 3.38 (1.09) | 0.22 (−0.69–1.13) | 0.63 |
| Lung | 3.63 (1.18) | 3.63 (1.18) | 3.63 (1.20) | 0.00 (−0.66–0.65) | 0.99 |
| Prostate | 2.87 (0.88) | 2.87 (0.92) | 2.87 (0.87) | 0.02 (−0.33–0.38) | 0.90 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| HADS Depression | |||||
| Colorectal | 5.70 (2.1) | 4.83 (0.98) | 5.75 (2.15) | 0.92 (−0.83–2.68) | 0.30 |
| Lung | 6.93 (2.84) | 7.13 (2.84) | 6.12 (2.75) | −1.01 (−2.58–0.56) | 0.20 |
| Prostate | 5.06 (1.57) | 4.97 (1.77) | 5.10 (1.46) | 0.16 (−0.48–0.79) | 0.62 |
| P-value (difference between disease sites) | ANOVA=0.0822 kw=0.0825 | ||||
| EORTC QLQ C-30 | |||||
| Physical functioning | |||||
| Colorectal | 85.52 (18.55) | 73.33 (19.78) | 86.26 (18.31) | 12.93 (−2.40–28.26) | 0.10 |
| Lung | 65.27 (27.34) | 63.79 (27.59) | 71.25 (26.30) | 7.46 (−7.74–22.65) | 0.33 |
| Prostate | 91.74 (14.96) | 91.97 (17.52) | 91.34 (13.68) | −0.63 (−6.69–5.45) | 0.84 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| Role functioning | |||||
| Colorectal | 82.06 (23.54) | 72.22 (27.22) | 82.66 (23.32) | 10.44 (−9.18–30.05) | 0.29 |
| Lung | 53.09 (39.89) | 53.59 (39.80) | 51.04 (41.49) | −2.55 (−24.84–19.74) | 0.82 |
| Prostate | 90.98 (19.45) | 88.46 (22.99) | 92.04 (17.49) | 3.58 (−4.28–11.44) | 0.37 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| Emotional functioning | |||||
| Colorectal | 77.78 (19.70) | 76.39 (12.27) | 77.86 (20.10) | 1.47 (−15.03–17.98) | 0.86 |
| Lung | 67.59 (26.48) | 67.82 (25.43) | 66.67 (31.33) | −1.15 (−15.96–13.65) | 0.88 |
| Prostate | 82.72 (18.38) | 79.27 (18.82) | 84.20 (18.24) | 4.93 (−2.44–12.30) | 0.19 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| Cognitive functioning | |||||
| Colorectal | 85.71 (17.52) | 91.67 (13.94) | 85.35 (17.70) | −6.31 (−20.94–8.31) | 0.39 |
| Lung | 72.84 (25.34) | 71.79 (26.34) | 77.08 (20.97) | 5.29 (−8.83–19.40) | 0.46 |
| Prostate | 88.07 (16.99) | 85.47 (19.93) | 89.30 (15.27) | 3.83 (−3.01–10.67) | 0.27 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| Social functioning | |||||
| Colorectal | 83.97 (22.51) | 75.00 (22.97) | 84.52 (22.58) | 9.52 (−9.25–28.30) | 0.32 |
| Lung | 63.37 (34.00) | 63.33 (34.38) | 63.54 (33.45) | 0.21 (−18.79–19.21) | 0.98 |
| Prostate | 91.74 (14.81) | 89.32 (17.31) | 92.79 (13.37) | 3.47 (−2.49–9.43) | 0.25 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
| Global Health Status | |||||
| Colorectal | 69.47 (18.64) | 59.72 (17.81) | 70.07 (18.61) | 10.35 (−5.15–25.84) | 0.19 |
| Lung | 51.34 (25.53) | 50.51 (25.25) | 54.69 (27.21) | 4.18 (−10.07–18.42) | 0.56 |
| Prostate | 76.99 (16.59) | 75.00 (20.23) | 77.61 (14.23) | 2.61 (−4.05–9.27) | 0.48 |
| P-value (difference between disease sites) | ANOVA=0.0001 kw=0.0001 | ||||
PCS=physical component summary of Short-Form 36; kw=Kruskal–Wallis rank sum test; MCS=mental component summary of Short-Form 36; ANOVA=analyses of variance; EORTC QLQ C-30=European Organization of Research and Treatment of Cancer quality of life core questionnaire; HADS=hospital anxiety and depression scale.
a
All patients referred with symptoms suggestive of cancer.
b
Patients for whom cancer was confirmed.
c
Patients for whom cancer was confuted.